3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
4
Multiple Myeloma
2
Vaccinia
1
Transplant-Related Hematologic Malignancy
1
Recurrence
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Glioma
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
22
Temozolomide
17
Specimen Handling
13
X-Rays
9
Biopsy
9
Radiotherapy
8
Radiation
8
trametinib
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Bevacizumab
6
larotrectinib
4
erdafitinib
4
dabrafenib
4
ulixertinib
3
palbociclib
3
abemaciclib
3
Surgical Procedures, Operative
3
Nivolumab
3
Cyclophosphamide
3
vorasidenib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
mirdametinib
2
lutetium Lu 177 dotatate
2
ivosidenib
2
fluorodopa F 18
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
90 days
×
Clear all
NCT03334305
2026-04-23
ACTION
University of Florida
Phase 1
Terminated
18 enrolled
11 charts